Terns Pharmaceuticals/$TERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Ticker
$TERN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
59
ISIN
US8808811074
Website
TERN Metrics
BasicAdvanced
$489M
-
-$1.08
-0.17
-
Price and volume
Market cap
$489M
Beta
-0.17
52-week high
$9.97
52-week low
$1.87
Average daily volume
939K
Financial strength
Current ratio
30.887
Quick ratio
30.568
Long term debt to equity
0.247
Total debt to equity
0.379
Profitability
EBITDA (TTM)
-103.56
Effective tax rate (TTM)
-0.28%
Management effectiveness
Return on assets (TTM)
-22.15%
Return on equity (TTM)
-32.12%
Valuation
Price to book
1.5
Price to tangible book (TTM)
1.5
Price to free cash flow (TTM)
-6.546
Free cash flow yield (TTM)
-15.28%
Free cash flow per share (TTM)
-85.55%
Growth
Earnings per share change (TTM)
-14.20%
3-year earnings per share growth (CAGR)
-18.66%
What the Analysts think about TERN
Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.
Bulls say / Bears say
Terns Pharmaceuticals has reported positive interim results from its Phase 1 CARDINAL study of TERN-701, indicating promising molecular responses and a favorable safety profile, with dose expansion planned for the first half of 2025. (Investing.com)
The company successfully completed an upsized public offering, raising approximately $150.15 million to fund the development of key product candidates, including TERN-701 and TERN-601. (Yahoo Finance)
Analysts have maintained an 'Outperform' rating for Terns Pharmaceuticals, citing the potential of TERN-701 for Chronic Myeloid Leukemia as a key catalyst, with price targets raised to $20.00. (Investing.com)
Terns Pharmaceuticals' stock has experienced significant volatility, hitting a 52-week low of $3.27 in March 2025, reflecting a 54% decline from its 52-week high of $11.40. (Investing.com)
The company faces intense competition in the obesity treatment market, with Eli Lilly's retatrutide demonstrating a mean weight reduction of up to 24.2% at 48 weeks, potentially overshadowing Terns' TERN-601. (Markets Insider)
Recent insider selling, including CFO Mark J. Vignola's sale of 9,059 shares in January 2025, may raise concerns about internal confidence in the company's future performance. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TERN Financial Performance
Revenues and expenses
TERN Earnings Performance
Company profitability
TERN News
AllArticlesVideos

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
GlobeNewsWire·4 weeks ago

3 Penny Stocks Wall Street Sees With 243% Upside
24/7 Wall Street·1 month ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Terns Pharmaceuticals stock?
Terns Pharmaceuticals (TERN) has a market cap of $489M as of July 18, 2025.
What is the P/E ratio for Terns Pharmaceuticals stock?
The price to earnings (P/E) ratio for Terns Pharmaceuticals (TERN) stock is 0 as of July 18, 2025.
Does Terns Pharmaceuticals stock pay dividends?
No, Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Terns Pharmaceuticals dividend payment date?
Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Terns Pharmaceuticals?
Terns Pharmaceuticals (TERN) has a beta rating of -0.17. This means that it has an inverse relation to market volatility.